Payment overview · 2025
General Payments
$115.95
5 reported records · 3 companies
Healthcare provider profile · identity verified
Vicky L Raisor, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LOUISVILLE, KY · NPI 1194181289
Verified facts
What the public records show
CMS Open Payments records show Vicky L Raisor, APRN received $115.95 in general payments during 2025 across 5 reported records.
ACADIA Pharmaceuticals Inc accounted for 42.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $48.90 | 42.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.55 | 31.5% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $30.50 | 26.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $115.95 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $48.90 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.55 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $30.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 840 | 71 |
| Gabapentin | Gabapentin | 480 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 320 | 47 |
| Mirtazapine | Mirtazapine | 249 | 51 |
| Atorvastatin Calcium | Atorvastatin Calcium | 236 | 45 |
| Eliquis | Apixaban | 210 | 23 |
| Potassium Chloride | Potassium Chloride | 198 | 47 |
| Lorazepam | Lorazepam | 195 | 58 |
| Divalproex Sodium | Divalproex Sodium | 194 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 191 | 29 |
| Levetiracetam | Levetiracetam | 191 | 27 |
| Trazodone Hcl | Trazodone Hcl | 190 | 39 |
| Warfarin Sodium | Warfarin Sodium | 185 | suppressed |
| Furosemide | Furosemide | 174 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 22 |
| Donepezil Hcl | Donepezil Hcl | 127 | 22 |
| Memantine Hcl | Memantine Hcl | 120 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 29 |
| Tramadol Hcl | Tramadol Hcl | 112 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 17 |
| Metformin Hcl | Metformin Hcl | 107 | 21 |
| Losartan Potassium | Losartan Potassium | 105 | 12 |
| Carvedilol | Carvedilol | 103 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 14 |
| Lacosamide | Lacosamide | 96 | suppressed |
| Omeprazole | Omeprazole | 92 | 19 |
| Sertraline Hcl | Sertraline Hcl | 79 | 17 |
| Clonazepam | Clonazepam | 78 | suppressed |
| Famotidine | Famotidine | 77 | 15 |
| Xarelto | Rivaroxaban | 75 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 71 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 15 |
| Nystatin | Nystatin | 64 | 22 |
| Risperidone | Risperidone | 62 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 11 |
| Baclofen | Baclofen | 58 | suppressed |
| Alprazolam | Alprazolam | 57 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 36 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Lisinopril | Lisinopril | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Pregabalin | Pregabalin | 50 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 49 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 49 | suppressed |
| Olanzapine | Olanzapine | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 17 |
| Morphine Sulfate | Morphine Sulfate | 44 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 42 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Ssd | Silver Sulfadiazine | 42 | 19 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Allopurinol | Allopurinol | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 36 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 23 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 34 | 14 |
| Glipizide | Glipizide | 32 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 32 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 30 | 11 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Calcitriol | Calcitriol | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Ubrelvy | Ubrogepant | 27 | suppressed |
| Zonisamide | Zonisamide | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 13 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Finasteride | Finasteride | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 15 | 12 |
| Glucagon Emergency Kit | Glucagon | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Atenolol | Atenolol | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115.95 · 5 records | ACADIA Pharmaceuticals Inc | INGREZZA, NUPLAZID, REXULTI | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error